Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

62.96 +0.08 (+0.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 637,015
Open 62.92
Bid (Size) 62.80 (1)
Ask (Size) 64.45 (2)
Prev. Close 62.88
Today's Range 62.43 - 64.85
52wk Range 20.63 - 82.00
Shares Outstanding 43,516,501
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
2 Biotech Stocks That Could Make You Richer
One is a well-established, large-cap drugmaker, while the other is still making a name for itself in the industry. 
Via The Motley Fool
Expert Ratings for Axsome Therapeutics
 
Via Benzinga

Performance

YTD
-14.13%
-14.13%
1 Month
-0.79%
-0.79%
3 Month
-15.31%
-15.31%
6 Month
+17.57%
+17.57%
1 Year
+82.81%
+82.81%

More News

Read More
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money
Via The Motley Fool
Biotech Stocks And The SVB Collapse — Here's What We Know
Via Investor's Business Daily
3 Nasdaq Stocks on Watch This Week
Via The Motley Fool
Is Axsome Therapeutics Stock a Buy Now?
Via The Motley Fool
Axsome Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Analyst Expectations for Axsome Therapeutics's Future
Via Benzinga
Axsome Therapeutics's Earnings: A Preview
Via Benzinga
5 Top Stocks for March
Via The Motley Fool
Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference
From Axsome Therapeutics, Inc.
Via Globe NewsWire
Axsome Therapeutics (AXSM) Q4 2022 Earnings Call Transcript
Via The Motley Fool
Why Axsome Therapeutics (AXSM) Shares Are Trading Higher
Via Benzinga
Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via Globe NewsWire
A New Bull Market Is in Sight: 3 Stocks to Buy Sooner Rather Than Later
Via The Motley Fool
Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
From Axsome Therapeutics, Inc.
Via Globe NewsWire
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Long Term Investor Alert: Lawsuit Against Directors Filed
Via SBWire
Meta Platforms Layoffs 2023: What to Know as Facebook Preps More Job Cuts
Via InvestorPlace
Axsome Therapeutics (AXSM) Stock Falls as Teva Pursues Generic Depression Drug
Via InvestorPlace
Earnings Scheduled For February 27, 2023
Via Benzinga
Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Via The Motley Fool
3 Surefire Growth Stocks You Can Buy Right Now
Via The Motley Fool
3 Stocks That Could Soar Whether There's a New Bull Market or Not
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.